Acta Pharmaceutica Sinica B

Scope & Guideline

Bridging Knowledge and Innovation in Pharmaceutics

Introduction

Explore the comprehensive scope of Acta Pharmaceutica Sinica B through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Acta Pharmaceutica Sinica B in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2211-3835
PublisherINST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
Support Open AccessYes
CountryChina
TypeJournal
Converge2012, from 2014 to 2024
AbbreviationACTA PHARM SIN B / Acta Pharm. Sin. B
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressC/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING 100050, PEOPLES R CHINA

Aims and Scopes

Acta Pharmaceutica Sinica B is a leading journal that focuses on the intersection of pharmaceutical sciences and biotechnology, emphasizing innovative drug discovery, development, and delivery methods. The journal aims to publish high-quality research that advances the understanding of medicinal chemistry, pharmacology, and therapeutic applications.
  1. Drug Discovery and Development:
    The journal covers innovative approaches in drug discovery, including small molecules, biologics, and traditional medicines, emphasizing their mechanisms of action and therapeutic potential.
  2. Nanomedicine and Drug Delivery Systems:
    Significant focus on nanotechnology for drug delivery, exploring the design, synthesis, and application of nanocarriers to enhance therapeutic efficacy and reduce side effects.
  3. Pharmacology and Toxicology:
    Research on the pharmacokinetics, pharmacodynamics, and toxicological evaluations of new drugs, providing insights into their safety and efficacy profiles.
  4. Biotechnology and Molecular Biology:
    Studies that leverage biotechnological advancements, including CRISPR and gene editing, for therapeutic purposes, particularly in cancer and genetic diseases.
  5. Phytochemistry and Natural Products:
    Exploration of bioactive compounds from natural sources, including their pharmacological effects, mechanisms of action, and potential for drug development.
  6. Clinical Translational Research:
    Research that bridges laboratory findings with clinical applications, focusing on the development of new therapeutic strategies and improving patient outcomes.
Acta Pharmaceutica Sinica B has seen a surge in research themes that reflect the latest trends and advancements in pharmaceutical sciences. These emerging scopes indicate a shift towards innovative methodologies and therapeutic strategies.
  1. Immunotherapy and Checkpoint Inhibition:
    Research focusing on immunotherapy, especially combination therapies that enhance immune response against tumors, has gained significant traction, indicating a paradigm shift in cancer treatment.
  2. Nanomedicine Innovations:
    There is a growing trend in the development of novel nanomedicine platforms for targeted drug delivery, including stimuli-responsive systems that enhance therapeutic efficacy and minimize side effects.
  3. CRISPR and Gene Editing Technologies:
    The application of CRISPR and other gene-editing technologies in drug development and disease treatment has emerged as a prominent theme, highlighting the potential for genetic therapies.
  4. Microbiome Research:
    Studies exploring the role of the gut microbiome in drug metabolism and therapeutic responses are gaining importance, reflecting a broader interest in personalized medicine.
  5. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is becoming increasingly prevalent, showcasing efforts to improve efficiency and accuracy in identifying potential drug candidates.
  6. Sustainable and Green Chemistry:
    Research emphasizing sustainable practices in drug development, including the use of renewable resources and eco-friendly processes, is on the rise, aligning with global sustainability goals.

Declining or Waning

While Acta Pharmaceutica Sinica B continues to thrive in numerous research areas, certain themes have shown signs of declining interest or publication frequency. These waning scopes reflect shifts in research focus and the evolving landscape of pharmaceutical sciences.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused on traditional drug formulations, as research shifts toward novel delivery systems and advanced drug formulations.
  2. Conventional Chemotherapy Approaches:
    The focus on conventional chemotherapy methods is waning in favor of targeted therapies and immunotherapies, indicating a shift toward more personalized medicine.
  3. Basic Pharmacognosy Studies:
    Research specifically centered on pharmacognosy without the application of modern techniques or translational potential has decreased, as the field moves towards integrating pharmacognosy with molecular biology.
  4. Single-Drug Therapy Studies:
    The decline in publications focusing solely on single-drug therapies suggests a growing interest in combination therapies and multi-target approaches to enhance treatment efficacy.

Similar Journals

DRUG DEVELOPMENT RESEARCH

Driving the evolution of medicine with impactful research.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

SCIENTIA PHARMACEUTICA

Fostering collaboration and discovery in pharmaceutical sciences.
Publisher: MDPIISSN: Frequency: 4 issues/year

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

BIOORGANIC & MEDICINAL CHEMISTRY

Connecting Molecular Insights to Clinical Applications
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0968-0896Frequency: 24 issues/year

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

Istanbul Journal of Pharmacy

Transforming ideas into impactful pharmaceutical solutions.
Publisher: ISTANBUL UNIV, FAC PHARMACYISSN: Frequency: 3 issues/year

Istanbul Journal of Pharmacy, published by Istanbul University, Faculty of Pharmacy, is a pivotal platform dedicated to the advancement of pharmaceutical sciences and technology. This journal serves as a vital resource for researchers, professionals, and students alike, seeking to disseminate cutting-edge research, reviews, and innovative methodologies within the pharmaceutical discipline. With a commitment to open access, the journal aims to foster a collaborative environment that promotes information sharing and scholarly discourse. The Istanbul Journal of Pharmacy invites submissions that delve into diverse topics ranging from drug formulation to pharmacokinetics, ensuring that readers are equipped with the latest insights and discoveries in the field. This journal is positioned to enhance scientific communication within the pharmaceutical community and support the continuous evolution of pharmacy practice and education globally.

Future Journal of Pharmaceutical Sciences

Transforming Research into Real-World Pharmaceutical Applications
Publisher: SPRINGERISSN: 2314-7245Frequency: 1 issue/year

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

International Journal of Pharmacology

Exploring the Depths of Drug Actions and Interactions
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Advancing pharmaceutical knowledge, one article at a time.
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0031-6903Frequency: 12 issues/year

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

CURRENT PHARMACEUTICAL DESIGN

Advancing Pharmaceutical Science for a Healthier Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Unlocking New Horizons in Pharmaceutical Research
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

Research in Pharmaceutical Sciences

Advancing Knowledge in Pharmacology and Beyond
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1735-5362Frequency: 6 issues/year

Research in Pharmaceutical Sciences is a premier, peer-reviewed journal published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of pharmacology, toxicology, and pharmaceutics. With an impact factor that positions it in the second quartile of its category (Q2) and a respectable rank of 23 out of 80 in Scopus, this journal serves as an essential platform for researchers, professionals, and students alike, providing open access since 2015 to a wealth of pioneering studies and comprehensive reviews. Based in Mumbai, India, the journal encompasses a diverse range of topics within the pharmaceutical sciences, offering insights that address both theoretical and practical challenges in drug development and safety. As it converges from 2009 to 2024, Research in Pharmaceutical Sciences continues to be a vital source of knowledge, promoting innovation and fostering collaboration within the global scientific community.